Cancer immunity and immunotherapy beyond COVID-19.
作者信息
Bellone Matteo, Brevi Arianna, Bronte Vincenzo, Dusi Silvia, Ferrucci Pier Francesco, Nisticò Paola, Rosato Antonio, Russo Vincenzo, Sica Antonio, Toietta Gabriele, Colombo Mario Paolo
机构信息
Unit of Cellular Immunology, I.R.C.C.S. Ospedale San Raffaele, Milan, Italy.
Immunology Section, Department of Medicine, University and Hospital Trust of Verona, Verona, Italy.
出版信息
Cancer Immunol Immunother. 2023 Jul;72(7):2541-2548. doi: 10.1007/s00262-023-03411-9. Epub 2023 Mar 30.
Abstract
摘要
相似文献
1
Cancer immunity and immunotherapy beyond COVID-19.新冠疫情之外的癌症免疫与免疫疗法。
Cancer Immunol Immunother. 2023 Jul;72(7):2541-2548. doi: 10.1007/s00262-023-03411-9. Epub 2023 Mar 30.
2
Cancer bio-immunotherapy XVIII annual NIBIT-(Italian network for tumor biotherapy) meeting, October 15-16, 2020.癌症生物免疫疗法第十八届年度NIBIT（意大利肿瘤生物治疗网络）会议，2020年10月15日至16日。
Cancer Immunol Immunother. 2022 Jul;71(7):1787-1794. doi: 10.1007/s00262-022-03145-0. Epub 2022 Jan 16.
3
Cancer bio-immunotherapy XVII annual NIBIT (Italian Network for Tumor Biotherapy) meeting, October 11-13 2019, Verona, Italy.癌症生物免疫疗法第十七届 NIBIT（意大利肿瘤生物治疗网络）年度会议，2019 年 10 月 11 日至 13 日，意大利维罗纳
Cancer Immunol Immunother. 2022 Jul;71(7):1777-1786. doi: 10.1007/s00262-021-03104-1. Epub 2021 Nov 9.
4
Cancer bio-immunotherapy XVI annual NIBIT-(Italian Network for Tumor Biotherapy) meeting, October 11-13 2018, Milan, Italy.癌症生物免疫疗法第十六届年度NIBIT（意大利肿瘤生物治疗网络）会议，2018年10月11日至13日，意大利米兰。
Cancer Immunol Immunother. 2020 Jun;69(6):1141-1151. doi: 10.1007/s00262-020-02502-1. Epub 2020 Feb 6.
5
"Cancer Bio-Immunotherapy in Siena": Twelfth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 9-11, 2014.“锡耶纳的癌症生物免疫疗法”：意大利肿瘤生物治疗网络（NIBIT）第十二次会议，2014年10月9日至11日于意大利锡耶纳召开
Cancer Immunol Immunother. 2016 Jan;65(1):119-26. doi: 10.1007/s00262-015-1699-z. Epub 2015 May 6.
6
"Cancer Bio-Immunotherapy in Siena": Thirteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 8-10, 2015.“锡耶纳的癌症生物免疫疗法”：意大利肿瘤生物治疗网络（NIBIT）第十三次会议，意大利锡耶纳，2015年10月8日至10日。
Cancer Immunol Immunother. 2016 Nov;65(11):1423-1431. doi: 10.1007/s00262-016-1899-1. Epub 2016 Sep 12.
7
Immune responses to SARS-CoV-2 in vaccinated patients receiving checkpoint blockade immunotherapy for cancer.接种疫苗的癌症患者在接受免疫检查点阻断免疫疗法时对 SARS-CoV-2 的免疫反应。
Front Immunol. 2022 Dec 13;13:1022732. doi: 10.3389/fimmu.2022.1022732. eCollection 2022.
8
Dendritic Cells and Their Role in Immunotherapy.树突状细胞及其在免疫疗法中的作用。
Front Immunol. 2020 May 21;11:924. doi: 10.3389/fimmu.2020.00924. eCollection 2020.
9
Future Research Goals in Immunotherapy.免疫疗法的未来研究目标
Surg Oncol Clin N Am. 2019 Jul;28(3):505-518. doi: 10.1016/j.soc.2019.02.006. Epub 2019 Apr 12.
10
Immunotherapy a New Hope for Cancer Treatment: A Review.免疫疗法：癌症治疗的新希望——综述
Pak J Biol Sci. 2018;21(3):135-150. doi: 10.3923/pjbs.2018.135.150.
本文引用的文献
1
Single-cell analysis of human non-small cell lung cancer lesions refines tumor classification and patient stratification.单细胞分析人类非小细胞肺癌病变可改善肿瘤分类和患者分层。
Cancer Cell. 2021 Dec 13;39(12):1594-1609.e12. doi: 10.1016/j.ccell.2021.10.009. Epub 2021 Nov 11.
2
Hallmarks of response, resistance, and toxicity to immune checkpoint blockade.免疫检查点阻断的反应、耐药和毒性的特征。
Cell. 2021 Oct 14;184(21):5309-5337. doi: 10.1016/j.cell.2021.09.020. Epub 2021 Oct 7.
3
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial.辅助阿特珠单抗治疗辅助化疗后切除的 IB-IIIA 期非小细胞肺癌（IMpower010）：一项随机、多中心、开放标签、III 期临床试验。
Lancet. 2021 Oct 9;398(10308):1344-1357. doi: 10.1016/S0140-6736(21)02098-5. Epub 2021 Sep 20.
4
Distinct mechanisms govern populations of myeloid-derived suppressor cells in chronic viral infection and cancer.慢性病毒感染和癌症中髓系来源的抑制性细胞群体受不同机制调控。
J Clin Invest. 2021 Aug 16;131(16). doi: 10.1172/JCI145971.
5
The T cell receptor repertoire of tumor infiltrating T cells is predictive and prognostic for cancer survival.肿瘤浸润 T 细胞的 T 细胞受体谱可预测和预测癌症的生存情况。
Nat Commun. 2021 Jul 2;12(1):4098. doi: 10.1038/s41467-021-24343-x.
6
T Cells Expressing Receptor Recombination/Revision Machinery Are Detected in the Tumor Microenvironment and Expanded in Genomically Over-unstable Models.在肿瘤微环境中检测到表达受体重组/修复机制的T细胞，并在基因组过度不稳定模型中扩增。
Cancer Immunol Res. 2021 Jul;9(7):825-837. doi: 10.1158/2326-6066.CIR-20-0645. Epub 2021 May 3.
7
Heme catabolism by tumor-associated macrophages controls metastasis formation.肿瘤相关巨噬细胞对血红素的分解代谢控制着转移的形成。
Nat Immunol. 2021 May;22(5):595-606. doi: 10.1038/s41590-021-00921-5. Epub 2021 Apr 26.
8
Integrated Genomic Analysis Identifies Driver Genes and Cisplatin-Resistant Progenitor Phenotype in Pediatric Liver Cancer.综合基因组分析鉴定儿童肝癌中的驱动基因和顺铂耐药前体细胞表型。
Cancer Discov. 2021 Oct;11(10):2524-2543. doi: 10.1158/2159-8290.CD-20-1809. Epub 2021 Apr 23.
9
How metabolism bridles cytotoxic CD8 T cells through epigenetic modifications.代谢如何通过表观遗传修饰来限制细胞毒性 CD8 T 细胞。
Trends Immunol. 2021 May;42(5):401-417. doi: 10.1016/j.it.2021.03.006. Epub 2021 Apr 15.
10
CTLA-4 blockade drives loss of T stability in glycolysis-low tumours.CTLA-4 阻断导致糖酵解低下肿瘤中 T 细胞稳定性丧失。
Nature. 2021 Mar;591(7851):652-658. doi: 10.1038/s41586-021-03326-4. Epub 2021 Feb 15.
Zotero 插件